ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
This Quarter Return
+4.74%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$485M
AUM Growth
+$485M
(-19%)
Cap. Flow
-$74.8M
Cap. Flow
% of AUM
-15.41%
Top 10 Holdings %
Top 10 Hldgs %
49.77%
Holding
309
New
41
Increased
54
Reduced
66
Closed
104
Top Buys
| 1 |
Inhibikase Therapeutics
IKT
|
$16.6M |
| 2 |
Zai Lab
ZLAB
|
$13.4M |
| 3 |
SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
|
$10.1M |
| 4 |
ABVX
Abivax
ABVX
|
$7.26M |
| 5 |
AVR
Anteris Technologies Global Corp. Common Stock
AVR
|
$5.88M |
Top Sells
| 1 |
Royalty Pharma
RPRX
|
$26.7M |
| 2 |
Cytokinetics
CYTK
|
$23.4M |
| 3 |
BridgeBio Pharma
BBIO
|
$21.1M |
| 4 |
Ascendis Pharma
ASND
|
$12.4M |
| 5 |
Immunovant
IMVT
|
$8.53M |
Sector Composition
| 1 | Healthcare | 80.2% |
| 2 | Financials | 3.47% |
| 3 | Communication Services | 1.36% |
| 4 | Utilities | 0.04% |
| 5 | Energy | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BBOT
26
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$713M
| $4.24M | 0.85% |
404,138
| – | – |
|
27
89bio
ETNB
$1.4B
| $4.03M | 0.81% |
515,138
+508,578
| +7,753% | +$3.98M |
|
28
Merus
MRUS
$5.04B
| $3.43M | 0.68% |
81,460
-71,826
| -47% | -$3.02M |
|
29
Kiniksa Pharmaceuticals
KNSA
$2.55B
| $3.29M | 0.66% |
166,406
-270,262
| -62% | -$5.35M |
|
30
Aldeyra Therapeutics
ALDX
$354M
| $3.23M | 0.65% |
647,960
+345,748
| +114% | +$1.73M |
|
31
Teva Pharmaceuticals
TEVA
$21.5B
| $3.23M | 0.65% |
146,671
+38,500
| +36% | +$849K |
|
32
Savara
SVRA
$567M
| $3.03M | 0.61% |
988,468
+245,834
| +33% | +$755K |
|
|
GRCE
33
Grace Therapeutics, Inc. Common Stock
GRCE
$41.8M
| $2.89M | 0.58% |
773,635
-185,936
| -19% | -$695K |
|
34
Monopar Therapeutics
MNPR
$213M
| $2.86M | 0.57% |
+130,037
| New | +$2.86M |
|
35
Crinetics Pharmaceuticals
CRNX
$3B
| $2.72M | 0.54% |
53,125
-35,300
| -40% | -$1.8M |
|
|
TECX
36
Tectonic Therapeutic, Inc. Common Stock
TECX
$318M
| $2.71M | 0.54% |
58,708
-68,451
| -54% | -$3.16M |
|
37
Rocket Pharmaceuticals
RCKT
$358M
| $2.66M | 0.53% |
211,400
+207,100
| +4,816% | +$2.6M |
|
|
CNTA
38
Centessa Pharmaceuticals
CNTA
$2.33B
| $2.58M | 0.52% |
154,027
+130,725
| +561% | +$2.19M |
|
|
JBIO
39
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $2.46M | 0.49% |
928,016
+814,941
| +721% | +$2.16M |
|
40
Korro Bio
KRRO
$199M
| $2.21M | 0.44% |
57,978
+8,527
| +17% | +$325K |
|
41
PTC Therapeutics
PTCT
$4.11B
| $2.17M | 0.43% |
48,023
+28,023
| +140% | +$1.26M |
|
|
ASPCU
42
A SPAC III Acquisition Corp. Unit
ASPCU
$60.1M
| $2.17M | 0.43% |
+215,000
| New | +$2.17M |
|
43
Xenon Pharmaceuticals
XENE
$3.04B
| $1.98M | 0.4% |
50,547
+22,644
| +81% | +$888K |
|
44
Apogee Therapeutics
APGE
$2.21B
| $1.87M | 0.37% |
41,274
-15,909
| -28% | -$721K |
|
45
RAPT Therapeutics
RAPT
$200M
| $1.86M | 0.37% |
1,174,313
+1,166,813
| +15,558% | +$1.84M |
|
46
Delcath Systems
DCTH
$389M
| $1.8M | 0.36% |
149,385
+118,333
| +381% | +$1.42M |
|
47
Pliant Therapeutics
PLRX
$98.8M
| $1.78M | 0.35% |
134,798
-111,330
| -45% | -$1.47M |
|
|
PVLA
48
Palvella Therapeutics, Inc. Common Stock
PVLA
$586M
| $1.74M | 0.35% |
144,641
| – | – |
|
49
Rhythm Pharmaceuticals
RYTM
$7.01B
| $1.73M | 0.35% |
+30,941
| New | +$1.73M |
|
50
Janux Therapeutics
JANX
$1.39B
| $1.69M | 0.34% |
31,509
+18,509
| +142% | +$991K |
|